SELLAS Life Sciences Group (NASDAQ:SLS) Downgraded by Zacks Investment Research to Hold

SELLAS Life Sciences Group stock has undergone multiple analysts rating changes in the recent past.  SELLAS Life Sciences Group Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of SELLAS Life Sciences Group traded down -$0.01 on Wednesday, reaching $8.91. 0 shares of the stock traded hands, compared to its average volume of 175927. Shares of SELLAS Life Sciences Group were trading at $8.91 on Wednesday. The firm’s 50 day moving average is $9.38 and its 200 day moving average is $9.02.SELLAS Life Sciences Group has a 12 month low of $8.79 and a 12 month high of $19.38. While on yearly highs and lows, SELLAS Life Sciences Group’s today has traded high as $9.11 and has touched $8.79 on the downward trend. See More Analyst Rating at: RATING

SELLAS Life Sciences Group Earnings and What to expect: 

SELLAS Life Sciences Group last posted its quarterly earnings data on August 12th, 2021. The reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.11. The company earned $1.90 million during the quarter. SELLAS Life Sciences Group has generated ($2.11) earnings per share over the last year (($1.27) diluted earnings per share). Earnings for SELLAS Life Sciences Group are expected to decrease in the coming year, from ($1.24) to ($1.75) per share. SELLAS Life Sciences Group has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 12th, 2021 based off prior year’s report dates.

Earnings for SELLAS Life Sciences Group are expected to decrease in the coming year, from ($1.24) to ($1.75) per share. The P/E ratio of SELLAS Life Sciences Group is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of SELLAS Life Sciences Group is -7.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. SELLAS Life Sciences Group has a P/B Ratio of 4.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

SELLAS Life Sciences Group (NASDAQ:SLS) Moving Average Technical Analysis

5 day Moving Average is $8.77 And 5 day price change is $0.47 (5.57%)  with average volume for 5 day average is 111,920. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $9.40 and 20 day price change is -$1.14 (-11.34%) and average 20 day moving volume is 158,195. 50 day moving average is $9.38  and 50 day price change is -$0.15 ( -1.66%)  and with average volume for 50 days is : 213,972. 200 day moving average is $9.02  and 200 day price change is $3.14 (54.42%)  and with average volume for 200 days is : 888,076.

Other owners latest trading in SELLAS Life Sciences Group :

  • On 8/25/2021 shares held by Marshall Wace LLP were 84,544 which equates to market value of $0.94M and appx 0.00% owners of SELLAS Life Sciences Group
  • On 8/23/2021 shares held by Morgan Stanley were 15,499 which equates to market value of $0.17M and appx 0.00% owners of SELLAS Life Sciences Group
  • On 8/17/2021 shares held by Price T Rowe Associates Inc. MD were 15,500 which equates to market value of $0.17M and appx 0.00% owners of SELLAS Life Sciences Group
  • In total Institutional ownership equates to Institutional Ownership Percentage: 12.81% for SELLAS Life Sciences Group

See More Analyst Rating at: RATING